ERAP1 Inhibition Reveals Novel MHC-Peptides for Targeting – Discovery, Pre- & Clinical Development Opportunities
Time: 10:15 am
day: Day 2
Details:
- We are global leaders in the therapeutic development of ERAP1 inhibitors, with clinical trials progressing in oncology
- ERAP1i changes the immunopeptidome on classical (HLA-A*, HLA-B*) and non classical (HLA-E, HLA-G) molecules to affect CD8 T cell and NK cell responses
- Pre-clinically, ERAP1i enables detection and quantification of novel tumor associated and viral peptides informing the development of peptide-MHC targeted therapeutics
- These datasets highlight novel development opportunities in oncology, virology and autoimmunity
